3. Treatment of ACS Part 2 (Working Diagnosis of STEMI vs NSTE ACS, Arabic Version)

In this video, the specific recommedations regarding the indications for revascularization and for pharmacotherapy are compared in the working diagnosis of STEMI vs. NSTE-ACS.

0:00 Reperfusion Indications in STEMI
9:17 Pharmacotherapy in STEMI
12:49 Fibrinolytic Therapy for STEMI
19:53 Reperfusion Indications in NSTE-ACS
22:53 Pharmacotherapy in NSTE-ACS

2023 ESC Guidelines for the Management of Acute Coronary Syndromes
https://www.escardio.org/Guidelines/C...


2023 ESC Guidelines for the management of acute coronary syndromes Supplementary data
https://oup.silverchair-cdn.com/oup/b...


Percutaneous Myocardial Revascularization in Late-Presenting Patients With STEMI
https://pubmed.ncbi.nlm.nih.gov/34556...


Mechanical Reperfusion and Long-term Mortality in Patients With Acute Myocardial Infarction Presenting 12 to 48 Hours From Onset of Symptoms.
https://jamanetwork.com/journals/jama...


Lack of benefit from percutaneous intervention of persistently occluded infarct arteries after the acute phase of myocardial infarction is time independent: insights from Occluded Artery Trial
https://www.ncbi.nlm.nih.gov/pmc/arti...


ST-segment-elevation myocardial infarction patients randomized to a pharmaco-invasive strategy or primary percutaneous coronary intervention: Strategic Reperfusion Early After Myocardial Infarction (STREAM) 1-year mortality follow-up
https://pubmed.ncbi.nlm.nih.gov/25161...


Fibrinolysis or Primary PCI in ST-Segment Elevation Myocardial Infarction. STREAM trial
https://www.nejm.org/doi/full/10.1056...


Five-year outcomes following timely primary percutaneous intervention, late primary percutaneous intervention, or a pharmaco-invasive strategy in ST-segment elevation myocardial infarction: the FAST-MI programme
https://pubmed.ncbi.nlm.nih.gov/31539...


ISAR-REACT 5 trial. Ticagrelor or Prasugrel in Patients with Acute Coronary Syndromes
https://pubmed.ncbi.nlm.nih.gov/31475...


Efficacy and safety of tenecteplase in combination with enoxaparin, abciximab, or unfractionated heparin: the ASSENT-3 randomised trial in acute myocardial infarction
https://pubmed.ncbi.nlm.nih.gov/11530...


GRACE ACS Risk and Mortality Calculator
https://www.mdcalc.com/calc/1099/grac...